Skip to main content

Table 2 Descriptive data of the population

From: Preliminary analysis of single-nucleotide polymorphisms in IL-10, IL-4, and IL-4Rα genes and profile of circulating cytokines in patients with gastric Cancer

Variable

Patients’ Groupa

n (%)

Healthy donors’ Group (%) (n = 30)

Sex

Female

5 (29.4)

7 (23.4)

Male

12 (70.6)

23 (76.6)

Age (years)

Mean

61.8

63.5

Range

(34–90)

(33–82)

Tumour stageb (Borrmann classification)

I

0

Does not apply

II

5 (38.4)

III

4 (30.8)

IV

4 (30.8)

Tumour typeb (Lauren classification)

Intestinal-type

Poorly differentiated

3 (23.0)

Moderately differentiated

3 (23.0)

Well differentiated

3 (23.0)

Diffuse

1 (8.0)

Not specified

3 (23.0)

Metastasisb

None

7 (53.8)

Lymphoid nodules (only)

0

Other organs

5 (38.5)

Both

1 (7.7)

Clinical evolutionb (Four years later)

Remission (alive)

7 (53.8)

Deceased

6 (46.2)

Survival Post diagnosisb,g Average (range, months)

IL-4 low levelb,c

Overall

6 (46.2); 33.2 (1–47)

Deceased (only)

2 (33.3)d; 13.5 (1–26)

IL-4 high levelb,e

Overall

7 (53.8); 26.4 (10–48)

Deceased (only)

4 (57.1)f; 13.0 (10–18)

Absence of IL-10 -1082 (G/A) SNPg

Overall

4 (40); 38.8 (26–42)

Deceased (only)

1 (25)h; 26.0

Presence of IL-10 -1082 (G/A) SNP

Homozygous or Heterozygousg

Overall

6 (60); 21.7 (1–47)

Deceased (only)

4 (66.7)i; 10.3 (1–18)

  1. aCases with data, n = 17; b Cases with data, n = 13. Data on patients not provided are subject to Institutional policies in keeping with National Legislation on Habeas data); c Less than 5 pg/mL; d Regarding the totality of patients with low level of IL-4; e Greater than 5 pg/mL (all cases above 12 pg/mL); f Regarding the totality of patients with high level of IL-4; g n = 10 (three cases showed no amplification band); h Regarding the totality of patients with Absence of IL-10 -1082 (G/A) SNP; i Regarding the totality of patients with Presence of IL-10 -1082 (G/A) SNP